Cargando…
Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study
Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increas...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539353/ https://www.ncbi.nlm.nih.gov/pubmed/31075857 http://dx.doi.org/10.3390/ijms20092292 |
_version_ | 1783422367729451008 |
---|---|
author | Gulati, Swati Wells, J. Michael Urdaneta, Gisel P. Balestrini, Kira Vital, Isabel Tovar, Katherine Barnes, Jarrod W. Bhatt, Surya P. Campos, Michael Krick, Stefanie |
author_facet | Gulati, Swati Wells, J. Michael Urdaneta, Gisel P. Balestrini, Kira Vital, Isabel Tovar, Katherine Barnes, Jarrod W. Bhatt, Surya P. Campos, Michael Krick, Stefanie |
author_sort | Gulati, Swati |
collection | PubMed |
description | Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets. |
format | Online Article Text |
id | pubmed-6539353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65393532019-06-04 Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study Gulati, Swati Wells, J. Michael Urdaneta, Gisel P. Balestrini, Kira Vital, Isabel Tovar, Katherine Barnes, Jarrod W. Bhatt, Surya P. Campos, Michael Krick, Stefanie Int J Mol Sci Article Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory airway disease punctuated by exacerbations (AECOPD). Subjects with frequent AECOPD, defined by having at least two exacerbations per year, experience accelerated loss of lung function, deterioration in quality of life and increase in mortality. Fibroblast growth factor (FGF)23, a hormone associated with systemic inflammation and altered metabolism is elevated in COPD. However, associations between FGF23 and AECOPD are unknown. In this cross-sectional study, individuals with COPD were enrolled between June 2016 and December 2016. Plasma samples were analyzed for intact FGF23 levels. Logistic regression analyses were used to measure associations between clinical variables, FGF23, and the frequent exacerbator phenotype. Our results showed that FGF23 levels were higher in frequent exacerbators as compared to patients without frequent exacerbations. FGF23 was also independently associated with frequent exacerbations (OR 1.02; 95%CI 1.004–1.04; p = 0.017), after adjusting for age, lung function, smoking, and oxygen use. In summary, FGF23 was associated with the frequent exacerbator phenotype and correlated with number of exacerbations recorded retrospectively and prospectively. Further studies are needed to explore the role of FGF 23 as a possible biomarker for AECOPD to better understand the pathobiology of COPD and to help develop therapeutic targets. MDPI 2019-05-09 /pmc/articles/PMC6539353/ /pubmed/31075857 http://dx.doi.org/10.3390/ijms20092292 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gulati, Swati Wells, J. Michael Urdaneta, Gisel P. Balestrini, Kira Vital, Isabel Tovar, Katherine Barnes, Jarrod W. Bhatt, Surya P. Campos, Michael Krick, Stefanie Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study |
title | Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study |
title_full | Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study |
title_fullStr | Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study |
title_full_unstemmed | Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study |
title_short | Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study |
title_sort | fibroblast growth factor 23 is associated with a frequent exacerbator phenotype in copd: a cross-sectional pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539353/ https://www.ncbi.nlm.nih.gov/pubmed/31075857 http://dx.doi.org/10.3390/ijms20092292 |
work_keys_str_mv | AT gulatiswati fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT wellsjmichael fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT urdanetagiselp fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT balestrinikira fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT vitalisabel fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT tovarkatherine fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT barnesjarrodw fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT bhattsuryap fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT camposmichael fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy AT krickstefanie fibroblastgrowthfactor23isassociatedwithafrequentexacerbatorphenotypeincopdacrosssectionalpilotstudy |